Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AEON Biopharma, Inc.AEON · Entity 7859 | PRINCIPAL ACCOUNTING OFFICER | February 17, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AEON Biopharma, Inc.
Report date February 17, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 575,251 |
Reported balance
After 2026-02-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 575,000 · Balance 575,251 F1: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 1,501,176 |
Reported balance
After 2026-03-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-04 · Grant · Acquired 925,925 · Balance 1,501,176 F2: Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
F2: Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 18:06 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 925,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024231 · tm268148-1_4seq1.xml · nonDerivative · entry 2 Sy Jennifer · CIK 0002023998 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,501,176 F2 · security: Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025. F2 · price: Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025. Read SEC document |
| February 17, 2026 Filed Mar 5, 2026 18:06 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 575,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024231 · tm268148-1_4seq1.xml · nonDerivative · entry 1 Sy Jennifer · CIK 0002023998 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,251 F1 · security: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. F1 · price: Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:55 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantRestricted Stock Units · Derivative | 925,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000135 · form4.xml · derivative · entry 1 Sy Jennifer · CIK 0002023998 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,925 Underlying: Class A Common Stock · 925,925 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date. F2 · derivative.exercise_date: 25% of the RSUs shall vest on each anniversary of May 21, 2025. F2 · derivative.expiration_date: 25% of the RSUs shall vest on each anniversary of May 21, 2025. Read SEC document |
| August 31, 2024 Filed Sep 4, 2024 21:53 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantStock Option · Derivative | 48,063 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001104659-24-097062 · tm2423415-4_4seq1.xml · derivative · entry 2 Sy Jennifer · CIK 0002023998 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,063 Underlying: Class A Common Stock · 48,063 shares Expires 2034-08-30 F2 · shares: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. F2 · derivative.exercise_date: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 4, 2024 21:53 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 18,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097062 · tm2423415-4_4seq1.xml · nonDerivative · entry 1 Sy Jennifer · CIK 0002023998 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,010 F1 · price: Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.